JDRF working to ease Brexit transition for people with type 1 diabetes
Type 1 diabetes charity JDRF has urged people with diabetes who rely on insulin not to stockpile medication in case of a no-deal Brexit.JDRF said it is working with the Department of Health and Social Care to find a solution should the situation become problematic once the UK exits Europe.
The charity added it is “committed to ensuring that the needs of people with type 1 diabetes are taken into account and prioritised”.
People who live in the UK receive their insulin from three main pharmaceutical manufacturers: Eli Lilly, Sanofi and Novo Nordisk. At the moment all analogue and synthetic human insulin is imported from outside the country and these are the most common forms of insulin used by people with diabetes in the UK.